Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves

Patient-reported outcomes, or PROs, are going to play a larger role in FDA cancer drug approvals, according to an expert in the field.

from Latest articles from Cancer Therapy Advisor Lung Cancer http://bit.ly/2SITscq